Scientific FAQ
Hard questions, short but rigorous answers.
These FAQ avoid slogans. Each answer distinguishes what is known, what is under study, and what would be incorrect to infer.
FAQ
Frequent scientific questions
Can stem cells cure many very different diseases?
No in any broad sense. There are specific established clinical uses, especially in hematology. Many other applications remain in research or clinical trials. Source basis: NIH, FDA, ISSCR.
Are iPSCs already standard therapies?
No. iPSCs are fundamental for disease modeling and translational research, but routine clinical use remains much more limited and complex.
If a treatment uses the patient's own cells, is it automatically safe?
No. Autologous does not automatically mean safe, appropriate or effective. Process, manipulation, indication and follow-up all matter.
Is an organoid a mini-organ ready for therapy?
No. An organoid reproduces some aspects of a tissue or organ, but it is not the same as a complete organ or a standard clinical intervention.
Why do FDA and ISSCR emphasize unapproved products so strongly?
Because regenerative medicine language can be used to market procedures that are not properly validated. The distinction between a clinical trial, a commercial offering and an approved therapy is essential.
Does the word "mesenchymal" always indicate a reliable therapy?
No. It is one of the most elastically used labels in marketing. The exact cell product and its regulatory status need to be defined clearly.